§360n–1. Priority review for qualified infectious disease products — Lineage
21 U.S.C. § 360n–1
How this provision came to be
-
Jul 9, 2012 Enacted Pub. L. 112–144 — Biosimilar User Fee Act of 2012
Release history
5 of 402 release points changed the text.
-
reading now Public Law 119-102
-
79 release points — no change to the text
-
Public Law 118-3 Text changed See what changed
-
213 release points — no change to the text
-
Public Law 114-321 Text changed See what changed
-
78 release points — no change to the text
-
Public Law 113-56 Text changed See what changed
-
8 release points — no change to the text
-
Public Law 113-21 Text changed See what changed
-
Jan 15, 2013 Public Law 112-283 Text changed
-
18 release points — not in the Code
-
Effective Date inferred